1
|
Lejeune M, Menard B, Servais S, Andrianne C, Capelle L, De Maistre S, Fabaron C, Cornier MF, Goutagny MP, Pereira M, Tardy C, Turquet E, Benakli M, Baudoux E, Evard S, Faucher C, Herrero G, Magro L, Geurten C. [Haematopoietic stem cell donation from minor donor: Respecting laws, assessing fitness, delivering information and good care (SFGM-TC)]. Bull Cancer 2024:S0007-4551(24)00152-8. [PMID: 38755034 DOI: 10.1016/j.bulcan.2024.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2024] [Revised: 03/19/2024] [Accepted: 04/02/2024] [Indexed: 05/18/2024]
Abstract
Haematopoietic stem cell collection from paediatric donors is a common and life-saving practice, as evidenced by the fact that there is a growing annual number of cases of transplants from minor donors among SFGM-TC centers over the last decade. Still, medical use of human tissue from a healthy and underage donor requires proper regulations and medical management. The guidelines below aim at underlining the importance of pondering the legal, medical and ethical aspects of using stem cells from healthy paediatric donors and stress out the importance of obtaining informed consent at the time of assessing HLA compatibility. Combined medical and psychological assessments are required before the donation, as well as one month later and one year later to ensure of the child's physical and mental wellbeing. Bone marrow harvest under general anaesthetics remains the preferred method of collection for children. Peripheral blood stem cell collection should only be considered for children who will not require a central venous access for collection. We aim at offering guidelines centered on the healthy child donating stem cells and his/her wellbeing, and these should be regularly reviewed as medical practices evolve.
Collapse
Affiliation(s)
- Marie Lejeune
- Service d'hématologie, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Bertille Menard
- Service d'hématologie pédiatrique, hôpital de la Timone Enfants, AP-HM, 264, rue Saint-Pierre, 13005 Marseille, France
| | - Sophie Servais
- Service d'hématologie, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Christelle Andrianne
- Service d'hématologie, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Lucie Capelle
- Service d'hématologie pédiatrique, CHU de Lille, avenue Eugène-Avinée, 59000 Lille, France
| | - Ségolène De Maistre
- Service d'hématologie pédiatrique, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France
| | - Catherine Fabaron
- Service d'onco-hematologie pédiatrique, CHU Purpan Toulouse, 1, place du Dr Baylac, 31300 Toulouse, France
| | - Marie Flata Cornier
- Service d'hémato-oncologie pédiatrique, hôpitaux universitaires de Genève, rue Willy-Donzé, 1203 Genève, Suisse
| | - Marie-Pierre Goutagny
- Service d'hématologie pédiatrique, IHOPe, 1, place Joseph-Renaut, 69008 Lyon, France
| | - Maguy Pereira
- Service d'hématologie, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Clea Tardy
- Service de pharmacie, hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75019 Paris, France
| | - Eric Turquet
- Service d'onco-hematologie pédiatrique, CHU de Rennes, Hôpital Sud, 16, boulevard de Bulgarie, 35200 Rennes, France
| | - Malek Benakli
- Coordinateur national du groupe algérien de travail sur la Greffe de cellules souches hématopoïétiques (GATGCSH), Centre Pierre et Marie Curie, rue Tebessi Larbi, Sidi M'Hamed, 16000 Alger, Algérie
| | - Etienne Baudoux
- Laboratoire de thérapie cellulaire et génique, centre hospitalier universitaire de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique
| | - Solène Evard
- Centre hospitalier universitaire de Rennes-Inserm, CIC-1414, centre d'investigation clinique de Rennes, 2, rue Henri-le-Guilloux, 35033 Rennes, France
| | - Catherine Faucher
- Agence de la biomédecine, 1, avenue du stade de France, 93212 Saint-Denis La Plaine cedex, France
| | - Gwenaelle Herrero
- Association de patients, rue de la Fontenette 23, 1227 Carouge,, Suisse
| | - Léonardo Magro
- LIRIC, Inserm U995, CHU de Lille, université de Lille, 59000 Lille, France
| | - Claire Geurten
- Service de pédiatrie, département d'hématologie pédiatrique, CHU de Liège, 1, avenue de l'Hôpital, 4000 Liège, Belgique.
| |
Collapse
|
2
|
Yafour N, Couturier MA, Borel C, Charbonnier A, Coman T, Fayard A, Masouridi-Levrat S, Yakoub-Agha I, Roy J. [Second allogeneic (update). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S29-S39. [PMID: 37045732 DOI: 10.1016/j.bulcan.2023.03.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 03/05/2023] [Accepted: 03/08/2023] [Indexed: 04/14/2023]
Abstract
Relapse after allogeneic hematopoietic cell transplantation (allo-HCT) remains a major concern because it is associated with poor survival. A second allo-HCT is a valid option in this situation. During the 13th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to update the second allo-HCT recommendations elaborated during the previous workshop (2016). The main indication for a second allo-HCT remains relapse of initial hematologic malignancy. Disease status; complete remission (CR), and relapse time after the first allo-HCT>6 months impact positively the overall survival of patients after the second allo-HCT. Donor change is a valid option, particularly if there is HLA loss on leukemic cells after a first haploidentical or following a mismatched allo-HCT is documented. Reduced intensity conditioning is recommended, while a sequential protocol is a reasonable option in patients with proliferative disease. A post-transplant maintenance strategy after hematological recovery is recommended as soon as day 60, even if the immunosuppressive treatment has not yet been stopped. Hypomethylating agents, and targeted therapies such as anti FLT3, anti BCL2, anti-IDH1/2, TKI, anti-TP53, anti-CD33, anti-CD19, anti-CD22, anti-CD30, check point inhibitors, and CAR-T cells can be used as a bridge to transplant or as an alternative treatment to the second allo-HCT.
Collapse
Affiliation(s)
- Nabil Yafour
- Établissement hospitalier et universitaire 1(er) Novembre 1954, faculté de médecine, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn Rochd, université d'Oran 1, Ahmed-Ben-Bella, 31000 Oran, Algérie.
| | - Marie-Anne Couturier
- Hôpital Morvan, institut cancérologie-hématologie, CHRU Brest, 2, avenue Foch, 29200 Brest, France
| | - Cécile Borel
- CHU de Toulouse, institut universitaire du cancer de Toulouse Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31059 Toulouse, France
| | - Amandine Charbonnier
- CHU d'Amiens, groupe hospitalier Amiens Sud, hématologie clinique et thérapie cellulaire, 80034 Amiens cedex 1, France
| | - Tereza Coman
- Institut Gustave-Roussy, département d'hématologie, 114, rue Edouard-Vaillant, Villejuif, France
| | - Amandine Fayard
- CHU de Clermont-Ferrand, service hématologie, 1, rue Lucie- et Raymond-Aubrac, 63003 Clermont-Ferrand, France
| | - Stavroula Masouridi-Levrat
- Hôpitaux universitaires de Genève, service d'hématologie, département d'oncologie, 4, rue Gabrielle-Perret-Gentil, 1205 Genève, Suisse
| | - Ibrahim Yakoub-Agha
- Inserm U1286, Infinite, CHU de Lille, université de Lille, 59000 Lille, France
| | - Jean Roy
- Hôpital maisonneuve-rosemont, université de Montréal, Montréal, Québec, Canada
| |
Collapse
|
3
|
Cornillon J, Crocchiolo R, Dubois V, Guidicelli G, Jorge-Cordeiro D, Meunier MC, Michiels S, Timmermans A, Villemonteix J, Yakoub-Agha I, Ahmad I. [Unrelated donor selection for allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2024; 111:S1-S13. [PMID: 37690877 DOI: 10.1016/j.bulcan.2023.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Revised: 07/18/2023] [Accepted: 07/19/2023] [Indexed: 09/12/2023]
Abstract
The selection of a donor is an essential element in allogeneic hematopoietic stem cell transplantation. In the absence of an HLA-matched related donor, the selection of an unrelated donor is considered, and is currently the most common type of allogenic donor used in practice. Many criteria are considered for the selection when multiple donors are available, particularly in case of partial match. The aim of this workshop is to assist in the selection of an unrelated donor, in keeping with recent data from the literature.
Collapse
Affiliation(s)
- Jérôme Cornillon
- Centre hospitalo-universitaire de Saint-Étienne 42, département d'hématologie et de thérapie cellulaire, Saint-Étienne, France.
| | | | | | | | - Debora Jorge-Cordeiro
- Université Paris-Cité, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Louis, laboratoire d'immunologie, Paris, France
| | - Marie-Christine Meunier
- Hôpital Maisonneuve-Rosemont, Optilab-CHUM, laboratoire de diagnostic moléculaire et cytogénétique, Montréal, Québec, Canada
| | - Sandra Michiels
- Hôpital universitaire de Bruxelles, institut Jules-Bordet, unité de transplantation-hématologie, Bruxelles, Belgique
| | - Aurélie Timmermans
- Hôpital universitaire de Bruxelles, institut Jules-Bordet, unité de transplantation-hématologie, Bruxelles, Belgique
| | - Juliette Villemonteix
- Université Paris-Cité, Assistance publique-Hôpitaux de Paris (AP-HP), hôpital Saint-Louis, laboratoire d'immunologie, Paris, France
| | - Ibrahim Yakoub-Agha
- CHU de Lille, Inserm U1286, Infinite, université de Lille, 59000 Lille, France
| | - Imran Ahmad
- Université de Montréal, hôpital Maisonneuve-Rosemont, institut universitaire d'hématologie-oncologie & de thérapie cellulaire, Montréal, Québec, Canada
| |
Collapse
|
4
|
Yafour N, Hamzy F, Elkababri M, Yakoub-Agha I, Bekadja MA. [Acute lymphoblastic leukemia in developing countries: Management from the transplant indication (allo/auto) until post-transplant follow-up. Guidelines from the SFGM-TC]. Bull Cancer 2023; 110:S30-S38. [PMID: 35562231 DOI: 10.1016/j.bulcan.2022.02.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2022] [Revised: 02/16/2022] [Accepted: 02/18/2022] [Indexed: 11/26/2022]
Abstract
Management of acute lymphoblastic leukemia (ALL) patients in countries with limited resources depends on the means of prognostic stratification, available treatment and logistics. During the 12th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines for allogeneic hematopoietic cell transplantation (Allo-HCT) in this disease. Conventional poor prognostic factors can be used to determine the indication of allo-HCT in first remission. Patients lacking a HLA-matched related donor can be allografted with a haploidentical donor allo-HCT if available. Chemotherapy based conditioning regimen can be used if TBI is not available, because the probability to find a radiotherapy department with the capacity for total body irradiation is low. For patients with Philadelphia chromosome positive (Phi+) ALL, post-transplantation tyrosine kinase inhibitors as a systematic maintenance strategy is recommended. Autologous HCT is optional for Phi+ ALL patients with negative minimal residual disease, who not eligible for allo-HCT. Patients with refractory/relapsed disease have a poor prognosis which highlights the importance of acquiring in the future new therapies such as: blinatumumab, inotuzumab, and CAR-T cells.
Collapse
Affiliation(s)
- Nabil Yafour
- Université d'Oran 1, Ahmed-Ben-Bella, établissement hospitalier et universitaire 1(er) Novembre 1954, faculté de médecine, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn-Rochd, 31000 Oran, Algérie.
| | - Faty Hamzy
- Hôpital Cheikh-Zaïd universitaire international, service d'hématologie et greffe, cité Al-Irfane-Hay Ryad avenue Allal-al-Fassi, 10000 Rabat, Maroc
| | - Maria Elkababri
- Hôpital d'enfants de Rabat, université Mohammed V de Rabat, service d'hématologie et oncologie pédiatrique, Rabat, Maroc
| | | | - Mohamed Amine Bekadja
- Université d'Oran 1, Ahmed-Ben-Bella, établissement hospitalier et universitaire 1(er) Novembre 1954, faculté de médecine, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn-Rochd, 31000 Oran, Algérie
| |
Collapse
|
5
|
Guenounou S, Aubrun C, Brancillon N, Bemben D, Chauvel C, Hounmenou N, Magro L, Porcheron S, Poullain M, De Bentzmann N, Gargallo G, Le Bars L, Mercier L, Yakoub-Agha I, Paul F. [National patient follow-up care logbook: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2021; 108:S87-S89. [PMID: 34756418 DOI: 10.1016/j.bulcan.2021.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 07/07/2021] [Accepted: 07/09/2021] [Indexed: 11/25/2022]
Abstract
In an attempt to harmonize clinical practices among francophone hematopoietic stem cell transplantation centers, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held its eleventh annual workshop series in September 2020 in Lille. This event brought together practitioners from across Europe. Our article discusses the updates and modifications for the 2021 version of the national patient follow-up care logbook.
Collapse
Affiliation(s)
- Sarah Guenounou
- CHU de Toulouse, institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France.
| | - Clotilde Aubrun
- CHU Ambroise-Paré, coordination Greffe-Hémato, 2, boulevard Kennedy, 7000 Mons, Belgique
| | - Nelly Brancillon
- CHU d'Angers, service d'hématologie, 4, rue Larrey, 49933 Angers, France
| | - Daphnée Bemben
- CHU de Lille, service d'hématologie, rue Michel-Polonovski, 59000 Lille, France
| | - Céline Chauvel
- Gustave-Roussy, service d'hématologie greffe, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - Nadège Hounmenou
- CHU de Nantes, hôpital enfant-adolescent, service d'onco-hématologie pédiatrique, quai Moncousu, 5(e) étage, 44093 Nantes cedex 1, France
| | - Leonardo Magro
- CHU de Lille, service d'hématologie, rue Michel-Polonovski, 59000 Lille, France
| | - Sophie Porcheron
- CLCC Henri-Becquerel, unité de soins intensifs hématologie, 1, rue d'Amiens, 76038 Rouen cedex, France
| | - Marie Poullain
- CHU de Toulouse, institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France
| | - Natacha De Bentzmann
- CHU de Toulouse, institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France
| | - Guillaume Gargallo
- CHU de Bordeaux, centre François-Magendie, service d'hématologie clinique et thérapie cellulaire, 33604 Pessac, France
| | - Laetitia Le Bars
- CHU Rennes Pontchaillou, hématologie clinique adultes, BMT HC avenue Henri-Le-Guilloux, 35033 Rennes cedex 09, France
| | - Lara Mercier
- CHU de Toulouse, institut universitaire du cancer de Toulouse - Oncopole, service d'hématologie, 1, avenue Irène-Joliot-Curie, 31000 Toulouse, France
| | | | - Franciane Paul
- CHU de Montpellier, Service d'hématologie, 80, avenue Augustin-Fliche, 34095 Montpellier, France
| |
Collapse
|
6
|
Yafour N, Bekadja MA, Chevallier P, Cabrera Q, Coman T, Elkababri M, Hamzy F, Quessar A, Laamiri A, Pochon C, Yakoub-Agha I, Harif M. [Establishment of Hematopoietic cell transplantation program in developing countries : Guidelines from the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC)]. Bull Cancer 2021; 108:S10-S19. [PMID: 34247762 DOI: 10.1016/j.bulcan.2021.02.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 02/23/2021] [Accepted: 02/24/2021] [Indexed: 12/26/2022]
Abstract
Hematopoietic cell transplantation (HCT) is the curative treatment for many malignant and non-malignant blood disorders and some solid cancers. However, transplant procedures are considered tertiary level care requiring a high degree of technicality and expertise and generating very high costs for hospital structures in developing countries as well as for patients without health insurance. During the 11th annual harmonization workshops of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines, for developing the transplant activity in emerging countries. Access to infrastructure must comply with international standards and therefore requires a hospital system already in place, capable of accommodating and supporting the HCT activity. In addition, the commitment of the state and the establishment for the financing of the project seems essential.
Collapse
Affiliation(s)
- Nabil Yafour
- Établissement hospitalier et universitaire 1(er) Novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn Rochd, université d'Oran 1, Ahmed Ben Bella, faculté de médecine, 31000 Oran, Algérie.
| | - Mohamed Amine Bekadja
- Établissement hospitalier et universitaire 1(er) Novembre 1954, service d'hématologie et de thérapie cellulaire, BP 4166 Ibn Rochd, université d'Oran 1, Ahmed Ben Bella, faculté de médecine, 31000 Oran, Algérie
| | - Patrice Chevallier
- CHU de Nantes, service d'hématologie clinique, Hôtel-Dieu, place Alexis-Ricordeau, 44035 Nantes, France
| | - Quentin Cabrera
- CHU Réunion Sud, service d'hématologie clinique, Site de Saint Pierre, La Réunion, France.
| | - Tereza Coman
- Institut Gustave-Roussy, département d'hématologie, 114, rue Edouard-Vaillant, Villejuif, France
| | - Maria Elkababri
- Hôpital d'enfants de Rabat, service d'hématologie et oncologie pédiatrique, université Mohammed V de Rabat, Maroc
| | - Faty Hamzy
- Hôpital Cheikh Zaïd universitaire international, service d'hématologie et greffe, Cite al Irfane-Hay Ryad avenue Allal al Fassi, 10000 Rabat, Maroc
| | - Asmaa Quessar
- Hôpital 20-Août de Casablanca, 6, rue Lahssen Elaarjoun, Casablanca 20250, Maroc
| | - Amal Laamiri
- Hôpital Cheikh Zaïd universitaire international, service d'hématologie et greffe, Cite al Irfane-Hay Ryad avenue Allal al Fassi, 10000 Rabat, Maroc
| | - Cécile Pochon
- Hôpital Brabois, service d'hémato-oncologie pédiatrique, rue du Morvan, 54500 Vandœuvre-les-Nancy, France
| | | | - Mhamed Harif
- Centre Hospitalier Tanger-Tétouan-Al Hoceima (Tanger), faculté de médecine et de pharmacie, Casablanca, Maroc
| |
Collapse
|
7
|
Urbain F, Labeyrie C, Castilla-Llorente C, Cintas P, Puma A, Maubeuge N, Puyade M, Farge D. [Autologous hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyneuropathy]. Rev Med Interne 2021; 42:639-649. [PMID: 33773849 DOI: 10.1016/j.revmed.2021.03.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2020] [Revised: 02/02/2021] [Accepted: 03/13/2021] [Indexed: 10/21/2022]
Abstract
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a dysimmune neuropathy with sensory and/or motor symptoms due to destruction of the myelin sheat secondary to an auto-immune attack. A quarter to a third of patients do not respond to immunomodulatory first line recommended therapies. No second line treatment has shown its effectiveness with a sufficient level of evidence. Autologous hematopoietic stem cell transplantation (AHSCT) is a promising therapy for autoimmune disease, especially for CIDP in recent works. We present in this article an update on the diagnosis of CIDP, its conventional treatments as well as the results of AHSCT in this indication, which was the subject of French recommendations under the aegis of the SFGMTC and neuromuscular disease french faculty (FILNEMUS) as a third line therapy after failure of two first-line and one second-line treatments.
Collapse
Affiliation(s)
- F Urbain
- Assistance Publique-Hôpitaux de Paris, Université Paris-Saclay, service de medecine interne, groupe hospitalier universitaire Paris Sud, hôpital Bicêtre, 94275 Le Kremlin-Bicêtre cedex, France.
| | - C Labeyrie
- Assistance Publique-Hôpitaux de Paris, centre de reference maladies rares neuropathies amyloïdes familiales et autres neuropathies peripheriques rares, service de neurologie, groupe hospitalier universitaire Paris Sud, hôpital Bicêtre, 94275 Le Kremlin-Bicêtre cedex, France
| | - C Castilla-Llorente
- Institut Gustave-Roussy, service d'hématologie, 114, rue Édouard-Vaillant, 94800 Villejuif, France
| | - P Cintas
- Explorations neurophysiologiques, centre SLA, centre de référence de pathologie neuromusculaire, CHU Toulouse, hôpital Pierre-Paul-Riquet, 31059 Toulouse Cedex, France
| | - A Puma
- Maladies du systeme nerveux peripherique et du muscle, Centre SLA, hôpital Pasteur 2-Zone C, CS 51069, 06001 Nice cedex 1, France
| | - N Maubeuge
- CHU de Poitiers, service de neurologie, 2, rue de la Milétrie, 86021 Poitiers cedex, France
| | - M Puyade
- CHU de Poitiers, service de médecine interne et maladies infectieuses, 2, rue de la Milétrie, 86021 Poitiers cedex, France; CHU de Poitiers, CIC-1402, 2, rue de la Milétrie, 86021 Poitiers cedex, France
| | - D Farge
- Unité de médecine interne, maladies auto-immunes et pathologie vasculaire UF04, Centre de référence des maladies auto-immunes systémiques rares d'Île-de-France MATHEC Hôpital Saint-Louis, UF04, Filière 'FAI2R', 1, avenue Claude-Vellefaux, 75475 Paris, France; Université de Paris, EA 3518, Paris, France; Département de Médecine, Université McGill, Montreal, QC, Canada
| |
Collapse
|
8
|
Allali S, Taylor M, Albinni S, Amiranoff D, de Montalembert M. Transfusing children with hemoglobinopathies. Transfus Clin Biol 2019; 26:147-149. [PMID: 31300265 DOI: 10.1016/j.tracli.2019.06.323] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2019] [Accepted: 06/25/2019] [Indexed: 11/29/2022]
Abstract
Thalassemia and sickle cell disease (SCD) are among the most common inherited diseases worldwide. Red blood cell transfusion is a cornerstone of their treatment, but its indications have significantly changed over the past years. New therapies are emerging in both syndromes: among them, hematopoietic stem cell transplantation is now routinely proposed, and gene therapy has shown promising preliminary results.
Collapse
Affiliation(s)
- S Allali
- Department of general pediatrics and pediatric infectious diseases, Paris Descartes university, Necker-Enfants malades hospital, AP-HP, 149, rue de Sèvres, 75015 Paris, France; Laboratory of excellence, GR-Ex, 75015 Paris, France; Pediatric reference center for sickle cell disease, 75015 Paris, France
| | - M Taylor
- Department of general pediatrics and pediatric infectious diseases, Paris Descartes university, Necker-Enfants malades hospital, AP-HP, 149, rue de Sèvres, 75015 Paris, France; Laboratory of excellence, GR-Ex, 75015 Paris, France; Pediatric reference center for sickle cell disease, 75015 Paris, France
| | - S Albinni
- Établissement français du sang, Necker-Enfants malades hospital, 149, rue de Sèvres, 75015 Paris, France
| | - D Amiranoff
- Établissement français du sang, Necker-Enfants malades hospital, 149, rue de Sèvres, 75015 Paris, France
| | - M de Montalembert
- Department of general pediatrics and pediatric infectious diseases, Paris Descartes university, Necker-Enfants malades hospital, AP-HP, 149, rue de Sèvres, 75015 Paris, France; Laboratory of excellence, GR-Ex, 75015 Paris, France; Pediatric reference center for sickle cell disease, 75015 Paris, France.
| |
Collapse
|
9
|
Tarillon S, Andrianne C, Balcaen S, Bole S, Genty C, Godin S, Lemarchand E, Mouchebeuf J, Mussot I, Wallart A, Alsuliman T, Desbrosses Y, El Cheikh J, Guerout-Verite MA, De Vos J, Tardieu L, Yakoub-Agha I, Porcheron S. [Graft reinjection: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2018; 106:S83-S91. [PMID: 30528618 DOI: 10.1016/j.bulcan.2018.11.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Revised: 10/31/2018] [Accepted: 11/01/2018] [Indexed: 11/28/2022]
Abstract
JACIE (Joint Accreditation Committee ISTC EBMT) regulations and standards impose a quality and safety requirement for graft reinjection by nurses. However, the standards do not provide a step-by-step graft reinjection procedure. Because of high medical team turnover, the opening of new transplant centers, and continual questions from colleagues trying to decipher the JACIE standards, the need for a specific procedure goes without saying. We collected graft reinjection procedures from each SFGM-TC center that participated in our survey, thus creating an inventory of the different steps that make up graft reinjection. In addition to reviewing the main regulatory texts and JACIE standards, we sought advice from medical and cellular therapy experts. We observed that most centers use a mix of practices and some unjustified practices. In some transplant units, it is still standard practice to defrost cell therapy products in the transplant unit. Caregivers are aware of the need for a rigorous application of the regulatory requirements and are willing to administer a procedure that provides specific steps for each stage of the process. In this workshop, we questioned each stage of the graft reinjection procedure, which helped us define clear methods of implementation. In the form of a checklist, we offer bone marrow and stem cell transplant units a step-by-step procedure.
Collapse
Affiliation(s)
- Sylvie Tarillon
- CHRU Brabois Nancy, unité de soins intensifs d'hématologie, rue du Morvan, 54511 Vandœuvre-lès-Nancy, France.
| | - Christelle Andrianne
- CHU de Liège, hématologie clinique, domaine de Saint-Tilmon B35, 4000 Liège, Belgique
| | - Sandie Balcaen
- CHRU de Lille, hôpital Huriez, service des maladies du sang, rue Michel Polonowski, 59000 Lille cedex, France
| | - Sarah Bole
- CHRU de Besançon, unité de soins intensifs hématologie, boulevard Fleming, 25000 Besançon, France
| | - Carole Genty
- CHRU Dupuytren, hématologie clinique et de thérapie cellulaire, 2, avenue Martin-Luther-King, 87042 Limoges cedex, France
| | - Sandrine Godin
- CHRU de Lille, hôpital Jeanne-de-Flandre, hématologie pédiatrique, avenue E.-Avinée, 59037 Lille cedex, France
| | - Eva Lemarchand
- CHU de Rouen, onco-hémato-pédiatrie, 1, rue de Germont, 76000 Rouen, France
| | - Jérôme Mouchebeuf
- Hôpital Pitié-Salpêtrière, unité de thérapie cellulaire, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - Isabelle Mussot
- CHRU de Besançon, unité de soins intensifs hématologie, boulevard Fleming, 25000 Besançon, France
| | - Anne Wallart
- CHRU de Lille, hôpital Huriez, service des maladies du sang, rue Michel-Polonowski, 59000 Lille cedex, France
| | - Tamim Alsuliman
- CHRU de Lille, hôpital Huriez, service des maladies du sang, rue Michel Polonowski, 59000 Lille cedex, France; Centre hospitalier de Boulogne-sur-Mer, 62321 Boulogne-sur-Mer, France
| | - Yohann Desbrosses
- CHRU de Besançon, unité de soins intensifs hématologie, boulevard Fleming, 25000 Besançon, France
| | - Jean El Cheikh
- American University of Beirut Medical Center, Beyrouth, Liban
| | | | - John De Vos
- CHU de Montpellier, hôpital Saint-Éloi, unité de thérapie cellulaire, 80, avenue Augustin-Fliche, 34295 Montpellier, France
| | - Laure Tardieu
- Centre hospitalier Dupuytren, service d'hématologie, 2, avenue Martin-Luther-King, 87042 Limoges cedex, France
| | - Ibrahim Yakoub-Agha
- CHRU de Lille, hôpital Huriez, service des maladies du sang, rue Michel Polonowski, 59000 Lille cedex, France; Université de Lille2, LIRIC, Inserm U995, 59000 Lille, France
| | - Sophie Porcheron
- Unité de soins intensifs, CLCC Becquerel, 1, rue d'Amiens, 76000 Rouen, France
| |
Collapse
|
10
|
Meyer A, Fornecker LM, Guffroy A, Korganow AS, Martin M. [Sinusoidal obstruction syndrome after BeAM conditioning regiment for autologous stem cell transplantation: Imputability of bendamustine? Report of two cases and literature review]. Rev Med Interne 2018; 39:882-885. [PMID: 29673920 DOI: 10.1016/j.revmed.2018.03.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2018] [Accepted: 03/03/2018] [Indexed: 11/29/2022]
Abstract
INTRODUCTION Sinusoidal obstruction syndrome is a rare complication of autologous hematopoietic stem cell transplantation. This syndrome is mainly described following conditioning regiment with busulfan, cyclophosphamide and/or total body irradiation. CASE REPORTS We report for the first time two cases of sinusoidal obstruction syndrome occurring lately after BeAM conditioning regiment (bendamustine, etoposide, aracytine, melphalan) for autologous stem cell transplantation in patients treated for malignant lymphoma. CONCLUSION Our observations highlight the difficulty to diagnose this complication with often non-specific clinical presentation and possible delayed occurrence after to transplantation, but also the therapeutic challenges, defibrotide being the only agent currently efficient. Physiopathology and potential responsibility of bendamustine in the sinusoidal obstruction syndrome occurrence will be discussed.
Collapse
Affiliation(s)
- A Meyer
- Service d'immunologie clinique et de médecine interne, centre national de référence des maladies auto-immunes rares, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France
| | - L-M Fornecker
- Service d'hématologie, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France
| | - A Guffroy
- Service d'immunologie clinique et de médecine interne, centre national de référence des maladies auto-immunes rares, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France
| | - A-S Korganow
- Service d'immunologie clinique et de médecine interne, centre national de référence des maladies auto-immunes rares, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France
| | - M Martin
- Service d'immunologie clinique et de médecine interne, centre national de référence des maladies auto-immunes rares, hôpitaux universitaires de Strasbourg, 67091 Strasbourg, France.
| |
Collapse
|
11
|
Kheder El-Fekih R, Deltombe C, Izzedine H. [Thrombotic microangiopathy and cancer]. Nephrol Ther 2017; 13:439-447. [PMID: 28774729 DOI: 10.1016/j.nephro.2017.01.023] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2016] [Revised: 01/03/2017] [Accepted: 01/05/2017] [Indexed: 01/28/2023]
Abstract
Thrombotic microangiopathy (TMA) is a group of disorders characterized by mechanical hemolytic anemia with thrombocytopenia and an ischemic organic lesion of variable and potentially fatal importance affecting mostly the kidneys and the brain with histologically a disseminated and occlusive microvasculopathy. The incidence of TMA represents 15% of acute kidney failure in oncological setting, largely due to the introduction of anti-angiogenic agents over the past decade. It may be more rarely related to cancer itself. The iatrogenic TMA can be classified into 2 types: The type I, secondary to chemotherapy (mitomycinC, gemcitabine), exposes to a chronic dose-dependent renal injury as well as an increase in morbidity and mortality; iatrogenic type II, secondary to anti-angiogenic agents', results in a dose-independent renal involvement and renal functional recovery is usual when the drug is discontinued. There is no randomized controlled trial to establish EBM-type management in TMA support. However, complement activation pathways and regulatory factors analyses allowed us to understand the mechanisms of endothelial lesions. As a result, the current trend includes the use of immunosuppressive agents in recurrent or plasmapheresis-refractory MAT.
Collapse
Affiliation(s)
| | - Clément Deltombe
- Service de néphrologie, immunologie clinique, transplantation, CHU Hôtel-Dieu, Place Alexis-Ricordeau, 44000 Nantes, France
| | - Hassan Izzedine
- Clinique internationale du Parc Monceau, 21, rue de Chazelles, 75017 Paris, France.
| |
Collapse
|
12
|
Thibert JB, Polomeni A, Yakoub-Agha I, Bordessoule D. [General and ethical considerations for the informed consent process: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer 2016; 103:S207-S212. [PMID: 27855949 DOI: 10.1016/j.bulcan.2016.09.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2016] [Accepted: 09/07/2016] [Indexed: 10/20/2022]
Abstract
Informed consent is not restricted to clinical research and must be applied to high-risk care such as hematopoietic stem cell transplantation. If standardized informed consent might improve inequalities in medical practices between different transplantation centers, it is strongly recommended that it be adapted with an honest dialogue between physicians and patients and physicians and donors. In an attempt to harmonize clinical practices among French hematopoietic stem cell transplantation centers, the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) held its sixth annual workshop series in September 2015 in Lille. This event brought together practitioners from across the country. The purpose of this paper is to highlight the French law concerning patients' rights and ethical practices for an informed consent process to be applied to care or research.
Collapse
Affiliation(s)
- Jean-Baptiste Thibert
- EFS Bretagne, unité de thérapie cellulaire, rue Pierre-Jean-Gineste, 35016 Rennes, France
| | - Alice Polomeni
- Assistance publique-Hôpitaux de Paris, hôpital Saint-Antoine, service d'hématologie clinique et thérapie cellulaire, 184, rue du Faubourg-St-Antoine, 75012 Paris, France
| | | | - Dominique Bordessoule
- CHU Dupuytren, université de Limoges, service d'hématologie clinique et de thérapie cellulaire, UMR CNRS 7276, 2, avenue ML-King, 87032 Limoges cedex, France.
| |
Collapse
|
13
|
Abstract
Under the long-term monitoring of patients treated in childhood or adolescence for cancer, we present in this article the long-term monitoring and therefore possible effects of patients who underwent allergenic hematopoietic stem cell transplantation. This article is based on a collaborative effort organized by the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC), which took place during the 4th day of allograft harmonization practices. Patients affected are children and young adults (0-25 years). We defined the monitoring effects beyond 1 year post-transplant. Our recommendations are based on a literature review, in line with the Leucémie Enfant Adulte (LEA) study cohort of long-term monitoring of patients treated for hematological malignancies in childhood, grafted or not. It became important to determine the nature of problems, their risk factors, frequency and monitoring necessary to implement for their detection. We will not address the therapeutic management of sequelae.
Collapse
Affiliation(s)
- Eva de Berranger
- Hôpital Jeanne-de-Flandre, unité d'hématologie pédiatrique, avenue Eugène-Avinée, 59037 Lille cedex, France.
| | - Charlotte Jubert
- Groupe hospitalier Pellegrin, hôpital des enfants, unité d'oncohématologie pédiatrique, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - Gérard Michel
- AP-HM, hôpital d'enfant de la Timone, service d'hématologie et oncologie pédiatrique, boulevard Jean-Moulin, 13385 Marseille cedex 05, France; AP-HM, Aix-Marseille université, département d'épidémiologie et économie de la santé publique et des maladies chroniques et de la qualité de l'unité de recherche sur la vie (EA3279), SPMC EA3279, 13385 Marseille cedex 05, France
| |
Collapse
|
14
|
de Berranger E, Michel G, Fahd M, Gandemer V, Jubert C, Marie-Cardine A, Pochon C, Rohrlich PS, Sirvent A, Cartigny M, Deschildre A, Yakoub-Agha I. [Managing late-effects after allogeneic stem cell transplantation in children: recommendations from the SFGM-TC]. ACTA ACUST UNITED AC 2014; 62:212-7. [PMID: 24973860 DOI: 10.1016/j.patbio.2014.05.009] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2014] [Accepted: 05/14/2014] [Indexed: 02/05/2023]
Abstract
In this report, we address the issue of late-effects after allogeneic stem cell transplantation in children. In an effort to harmonize clinical practices between different French transplantation centers, the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC) set up the fourth annual series of workshops which brought together practitioners from all member centers and took place in September 2013 in Lille.
Collapse
Affiliation(s)
- E de Berranger
- Service d'hématologie pédiatrique, hôpital Jeanne-de-Flandre, CHRU, avenue Oscar-Lambret, 59037 Lille cedex, France
| | - G Michel
- Service d'hématologie pédiatrique, hôpital d'Enfants de la Timone, boulevard Jean-Moulin, 13385 Marseille cedex 05, France
| | - M Fahd
- Unité d'hématologie-immunologie, hôpital Robert-Debré, 48, boulevard Serrurier, 75019 Paris, France
| | - V Gandemer
- Service d'hémato-oncologie pédiatrique, hôpital Sud, 16, boulevard de Bulgarie, BP 56129, 35056 Rennes cedex, France
| | - C Jubert
- Unité d'onco-hématologique pédiatrique, hôpital des Enfants, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France
| | - A Marie-Cardine
- Service d'immuno-hémato-oncologie pédiatrique, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France
| | - C Pochon
- Hématologie, unité de transplantation médullaire allogénique, CHU de Nancy, avenue de la Forêt-de-Haye, 54500 Vandœuvre-Lès-Nancy, France
| | - P S Rohrlich
- Médecine interne-hématologie, clinique hôpital de l'Archet, 151, route de Saint-Antoine-de-Ginestière, 06200 Nice cedex 03, France
| | - A Sirvent
- Hématologie et d'oncologie médicale, hôpital Lapeyronie, CHU, avenue du Doyen-Giraud, 34275 Montpellier cedex, France
| | - M Cartigny
- Service d'endocrinologie pédiatrique, pôle Enfant, hôpital Jeanne-de-Flandre, avenue Eugène-Avinée, 59037 Lille cedex, France
| | - A Deschildre
- Service de pneumologie pédiatrique, pôle Enfant, hôpital Jeanne-de-Flandre, avenue Eugène-Avinée, 59037 Lille cedex, France
| | - I Yakoub-Agha
- Maladies du sang, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France.
| |
Collapse
|